Delayed-Release Oral Mesalamine at 4.8 g/day (800 mg tablet) for the Treatment of Moderately Active Ulcerative Colitis: The ASCEND II Trial

Hanauer, Stephen B.; Sandborn, William J.; Kornbluth, Asher; Katz, Seymour; Safdi, Michael; Woogen, Scott; Regalli, Gino; Yeh, Chyon; Smith-Hall, Nancy; Ajayi, Funmilay
November 2005
American Journal of Gastroenterology;Nov2005, Vol. 100 Issue 11, p2478
Academic Journal
BACKGROUND AND AIMS: Preliminary data have shown that delayed release oral mesalamine (Asacol®) dosed at 4.8 g/day provided additional efficacy benefit compared to 1.6 g/day in patients with mildly to moderately active ulcerative colitis. Additionally, Asacol dosed at 2.4 g/day has been proved to be more effective than 1.6 g/day. Whether 4.8 g/day of mesalamine (dosed with an investigational 800 mg tablet) is more effective than Asacol 2.4 g/day (dosed with a 400 mg tablet) in patients with moderately active ulcerative colitis is unknown. METHODS: A randomized, double-blind, controlled trial (ASCEND II) was conducted to evaluate the efficacy of 4.8 g/day of mesalamine in adults with active ulcerative colitis. Three hundred eighty-six patients with mild to moderate ulcerative colitis were randomized for treatment with mesalamine 2.4 g/day (400 mg tablet) or 4.8 g/day (800 mg tablet) for 6 wk. The primary efficacy population was 268 patients with moderately active ulcerative colitis treated with 2.4 g/day (n = 139) or 4.8 g/day (n = 129). The primary endpoint was the proportion of patients in each treatment group that achieved overall improvement (“treatment success,” defined as either complete remission or a clinical response to therapy) from baseline at week 6. RESULTS: Seventy-two percent of patients receiving 4.8 g/day of mesalamine for moderate ulcerative colitis (89/124 patients) achieved treatment success at week 6, compared with 59% of those who received 2.4 g/day (77/130 patients) ( p= 0.036). Both regimens were well tolerated. Adverse events and clinically significant changes in laboratory results were similar in both treatment groups. CONCLUSIONS: Patients with moderately active ulcerative colitis treated with 4.8 g/day of mesalamine (800 mg tablet) are significantly more likely to achieve overall improvement at 6 wk compared to patients treated with 2.4 g/day.


Related Articles

  • Correlation of Serum Soluble TNF-α Receptors I and II Levels with Disease Activity in Patients with Ulcerative Colitis. Hanai, Hiroyuki; Watanabe, Fumitoshi; Yamada, Masami; Sato, Yoshihiko; Takeuchi, Ken; Iida, Takayuki; Tozawa, Kotaro; Tanaka, Tatsuo; Maruyama, Yasuhiko; Matsushita, Isao; Iwaoka, Yasushi; Saniabadi, Abby // American Journal of Gastroenterology;Aug2004, Vol. 99 Issue 8, p1532 

    OBJECTIVES: TNF-α has a major role in inflammatory bowel disease via two receptors, p55 (RI) and p75 (RII) expressed on many cell types, in particular neutrophils and monocytes (GM). Upon activation of these leukocytes, RI and RII are shed into the medium and can neutralize TNF. Accordingly,...

  • Are pANCA, ASCA, or Cytokine Gene Polymorphisms Associated with Pouchitis? Long-term Follow-up in 102 Ulcerative Colitis Patients. Aisenberg, James; Legnani, Peter E.; Nilubol, Naris; Cobrin, Gena M.; Ellozy, Sharif H.; Hegazi, Refaat A.F.; Yager, Jessica; Bodian, Carol; Gorfine, Stephen R.; Bauer, Joel J.; Plevy, Scott E.; Sachar, David B. // American Journal of Gastroenterology;Mar2004, Vol. 99 Issue 3, p432 

    OBJECTIVE: Pouchitis is the most frequent complication after ileal pouch-anal anastomosis for ulcerative colitis. This study aims to analyze the frequency and characteristics of pouchitis in long-term follow-up in a large population, and to determine whether a significant association exists...

  • Aminosalicylate (Major drug group).  // Royal Society of Medicine: Medicines;2002, p52 

    The article provides information on aminosalicylate agents, a chemical class of drugs that contain a 5-aminosalicylic acid component. They are used to maintain remission of the symptoms of ulcerative colitis, also to treat active Crohn's disease; also, they can be used to treat rheumatoid...

  • Inflammatory Bowel Disease. Nasseri-Moghaddam, Siavosh // Middle East Journal of Digestive Diseases;Apr2012, Vol. 4 Issue 2, p77 

    Inflammatory bowel disease (IBD) is the term used for a group of diseases with yet unknown etiology, prevalence of which is increasing almost everywhere in the world. The disease was almost non-existent four decades ago in the east, including the middle-east, while now a days it is seen more and...

  • The Microvacular Thrombi of Colonic Tissue in Ulcerative Colitis. Guobin He; Qin Ouyang; Daiyun Chen; Fengyuan Li; Jingguo Zhou // Digestive Diseases & Sciences;Sep2007, Vol. 52 Issue 9, p2236 

    Abstract  Mucosal microvacular thrombi in rectal biopsies were observed in some ulcerative colitis (UC). Heparin may be effective in steroid resistant UC in some studies, however, the new results of meta-analysis demonstrated a non-significant effect of heparin in controlled...

  • Meta-Analysis of the Placebo Response in Ulcerative Colitis. Sagar Garud; Alphonso Brown; Adam Cheifetz; Emily Levitan; Ciaran Kelly // Digestive Diseases & Sciences;Apr2008, Vol. 53 Issue 4, p875 

    Abstract   Purpose The placebo response rate in randomized controlled trials (RCTs) in ulcerative colitis (UC) varies from 0 to 76%. The aims of this study were to quantify the pooled placebo response rate and identify the factors affecting it. Methods We performed a...

  • Abnormalities in colonic mucin may contribute to the persistence of colonic mucosal inflammation.  // Journal of Gastroenterology;2000, Vol. 35 Issue 1, p71 

    Editorial. Deals with the possible contribution of the abnormalities in colonic mucin to the persistence of colonic mucosal inflammation. Percentage of ulcerative colitis patients with circulating antibodies to colonocytes; Number of reported mucin genes; Description of MUC2 mucin; Candidate...

  • A Population-based Ecologic Study of Inflammatory Bowel Disease: Searching for Etiologic Clues. Chris Green; Lawrence Elliott; Carole Beaudoin; Charles N. Bernstein // American Journal of Epidemiology;Oct2006, Vol. 164 Issue 7, p615 

    The authors' objective in this study was to determine geographic variations in the incidence of inflammatory bowel disease (IBD), specifically Crohn's disease and ulcerative colitis, in the Canadian province of Manitoba and its association with the sociodemographic, geographic, and...

  • Dramatic And Long Lasting Efficiency (13 Years) Of Oral 5 Aspirin. Maroy, Bernard // Internet Journal of Academic Physician Assistants;2003, Vol. 3 Issue 1, p12 

    Introduction: Could 5 ASA be an option in case of cortico-resistant and/or intolerant ulcerative colitis? Case report: A 55-year-old woman was referred for a recent, moderately severe, left-sided ulcerative colitis. The response to corticotherapy was initially fair, then mediocre, complicated by...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics